The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question ...

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Pfizer PFE offers a high dividend yield, making it appealing to income‑focused investors who prioritize steady cash returns over rapid growth. The drugmaker, whose products include antiviral ...

Pfizer has settled patent disputes with Cipla, Dexcel Pharma, and Hikma Pharmaceuticals over Vyndamax, extending U.S. exclusivity to June 1, 2031. The deal averts earlier generic entry and stabilizes ...

The world’s biggest pharma companies recorded their best weekly performance in years on Friday after Pfizer (NYSE:PFE) reached a landmark drug pricing deal with the U.S. government, agreeing to sell ...

Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to ...

NEW YORK, N.Y. — Pfizer announced Wednesday that data shows a third dose of its COVID-19 vaccine can “strongly” boost protection against the highly transmissible delta variant. The pharmaceutical and ...

Pfizer Inc. and Novo Nordisk A/S boosted their bids for obesity startup Metsera Inc. Novo’s updated offer values Metsera at a total of $10 billion, compared to the offer from Pfizer, which values the ...

Recon: Pfizer to boost US vaccine deliveries as EU secures more doses; Tango to go public in $353M SPAC deal Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.